GENELUX CORPORATION Operating Expenses
GENELUX CORPORATION (GNLX) reported Operating Expenses of $9.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- GENELUX CORPORATION operating expenses for the quarter ending 2026-06-30 was $9.64M, a 23.78% increase year-over-year.
- GENELUX CORPORATION operating expenses for the quarter ending 2026-03-31 was $9.17M, a 17.34% increase year-over-year.
- GENELUX CORPORATION operating expenses for the quarter ending 2025-12-31 was $9.42M, a 3.36% decline year-over-year.
- GENELUX CORPORATION operating expenses for the quarter ending 2025-09-30 was $8.19M, a 18.05% increase year-over-year.
- GENELUX CORPORATION operating expenses for fiscal 2025 was $33.22M, a 4.79% increase from fiscal 2024.
- GENELUX CORPORATION operating expenses for fiscal 2024 was $31.70M, a 30.28% increase from fiscal 2023.
- GENELUX CORPORATION operating expenses for fiscal 2023 was $24.34M, a 72.82% increase from fiscal 2022.
- GENELUX CORPORATION operating expenses for fiscal 2022 was $14.08M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.64M 10-Q · filed 2026-08-13 | $18.82M 10-Q · filed 2026-08-13 | $28.24M derived: sum of 3 quarters · filed 2026-08-13 | $36.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $9.17M 10-Q · filed 2026-05-07 | $18.59M derived: sum of 2 quarters · filed 2026-05-07 | $26.79M derived: sum of 3 quarters · filed 2026-05-07 | $34.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $9.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $17.61M derived: sum of 2 quarters · filed 2026-03-19 | $25.41M derived: sum of 3 quarters · filed 2026-08-13 | $33.22M 10-K · filed 2026-03-19 |
| 2025-09-30 | $8.19M 10-Q · filed 2025-11-05 | $15.99M derived: sum of 2 quarters · filed 2026-08-13 | $23.80M 10-Q · filed 2025-11-05 | $33.55M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $7.79M 10-Q · filed 2026-08-13 | $15.61M 10-Q · filed 2026-08-13 | $25.36M derived: sum of 3 quarters · filed 2026-08-13 | $32.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $7.82M 10-Q · filed 2026-05-07 | $17.56M derived: sum of 2 quarters · filed 2026-05-07 | $24.50M derived: sum of 3 quarters · filed 2026-05-07 | $31.40M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $16.69M derived: sum of 2 quarters · filed 2026-03-19 | $23.58M derived: sum of 3 quarters · filed 2026-03-19 | $31.70M 10-K · filed 2026-03-19 |
| 2024-09-30 | $6.94M 10-Q · filed 2025-11-05 | $13.83M derived: sum of 2 quarters · filed 2025-11-05 | $21.96M 10-Q · filed 2025-11-05 | $28.96M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $6.89M 10-Q · filed 2025-08-07 | $15.02M 10-Q · filed 2025-08-07 | $22.02M derived: sum of 3 quarters · filed 2025-08-07 | $27.32M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $8.12M 10-Q · filed 2025-05-06 | $15.12M derived: sum of 2 quarters · filed 2025-05-06 | $20.43M derived: sum of 3 quarters · filed 2025-05-06 | $25.83M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $12.31M derived: sum of 2 quarters · filed 2025-03-28 | $17.70M derived: sum of 3 quarters · filed 2025-03-28 | $24.34M 10-K · filed 2025-03-28 |
| 2023-09-30 | $5.31M 10-Q · filed 2024-11-14 | $10.70M derived: sum of 2 quarters · filed 2024-11-14 | $17.33M 10-Q · filed 2024-11-14 | $20.50M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $5.39M 10-Q · filed 2024-08-14 | $12.03M 10-Q · filed 2024-08-14 | $15.19M derived: sum of 3 quarters · filed 2024-08-14 | $19.84M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $6.63M 10-Q · filed 2024-05-09 | $9.79M derived: sum of 2 quarters · filed 2024-05-09 | $14.45M derived: sum of 3 quarters · filed 2024-05-09 | $17.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $7.82M derived: sum of 2 quarters · filed 2024-03-29 | $10.62M derived: sum of 3 quarters · filed 2024-03-29 | $14.08M 10-K · filed 2024-03-29 |
| 2022-09-30 | $4.66M 10-Q · filed 2023-11-14 | $7.46M derived: sum of 2 quarters · filed 2023-11-14 | $10.92M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $2.80M 10-Q · filed 2023-08-14 | $6.26M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $3.46M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |